Pharmaceuticals

Neuragenex Expands to Open New Texas Location, Giving More People Access to its Innovative Approach to Chronic Pain Management

VICTORIA and WACO, Texas, Aug. 8, 2023 /PRNewswire/ -- Neuragenex, a trailblazing pain management practice at the forefront of pain management solutions, is delighted to announce the opening of theWaco and Victoria clinic locations inTexas. With its groundbreaking approach to chronic pain managem...

2023-08-09 00:03 1761

Vatech Announces Distribution Through Henry Schein to Help Oral Health Professionals Enhance Access to Cutting-Edge Imaging Solutions

HWASEONG, South Korea, Aug. 8, 2023 /PRNewswire/ -- Vatech, a global leader in the dental imaging market, has announced that its products will be distributed byHenry Schein, helping to expand the availability of its cutting-edge products for dental clinics inNorth America. Vatech's portfolio o...

2023-08-08 21:00 2997

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updat...

2023-08-08 20:00 2341

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2023-08-08 16:10 3572

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors

* Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX * $100 million financing upfront wi...

2023-08-07 23:14 4308

Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer

BEIJING, SHANGHAI and BOSTON, Aug. 7, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that Jacobio's in-house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug ...

2023-08-07 20:03 3057

DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors

SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, today announ...

2023-08-07 18:00 2255

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb). As a result, BioCity Biopharma will...

2023-08-07 16:14 2143

The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC

HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that eClinical Medicine(IF:15.1), a sub-j...

2023-08-07 12:29 3014

Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

ROCKVILLE, Md. and SUZHOU, China, Aug. 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that lisaftoclax (APG-2575), a novel Bcl-2 inhibitor...

2023-08-07 09:43 2639

JinMed's Nanobathing Products Receive Multiple Patent Certifications and Sign Directed Procurement Agreement with Shanghai Zhongjin HongKang Medical Technology

CHANGZHOU, China, Aug. 3, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("the Company" or "JinMed") (NASDAQ: ZJYL) which is the world's leading provider of rehabilitation equipment. Currently, the Company's nanobathing products have been granted an invention patent and four utility model pa...

2023-08-03 17:13 2010

ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress

SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinic...

2023-08-03 11:43 2171

SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation

Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a global big biotech SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation o...

2023-08-03 07:30 2366

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough c...

2023-08-03 07:00 2428

Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System

SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced onJuly 31, 2023 that the first Chinese patient of the multi-center ...

2023-08-01 20:00 3657

Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA

HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...

2023-08-01 17:08 1827

Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC

* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...

2023-08-01 00:00 2574

Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together

BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...

2023-07-31 20:30 3242

111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow

SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...

2023-07-31 17:59 2605

Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)

NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...

2023-07-31 17:05 4606
1 ... 109110111112113114115 ... 165